Skip to main content
Log in

Nefazodone: a better tolerated option than TCAs for major depression

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. Am J Psychiatry 1994; 151: 979–86

    PubMed  CAS  Google Scholar 

  2. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992 Nov 14; 305: 1198–202

    Article  PubMed  CAS  Google Scholar 

  3. British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar: 172–81

  4. PDR Generics. 3rd ed. Montvale NJ: Medical Economics, 1997

  5. Davis R, Whittington R, Bryson H. Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997 Apr; 53(4): 608–36

    Article  PubMed  CAS  Google Scholar 

  6. A place on the formulary for SSRIs in the treatment of depression. Drug Ther Perspect 1996; 8(6): 13–6

    Google Scholar 

  7. Venlafaxine: another option in major depression. Drug Ther Perspect 1995; 5(12): 1–4

    Google Scholar 

  8. Paroxetine in depression: improved tolerability over TCAs may offset higher acquisition costs. Drug Ther Perspect 1994; 3(5): 5–7

    Google Scholar 

  9. D’Amico MF, Roberts DL, Robinson DS, et al. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. Psychopharmacol Bull 1990; 26(1): 147–50

    PubMed  Google Scholar 

  10. Marcus RN, Mendels J. Nefazodone in the treatment of severe, melancholic, and recurrent depression. J Clin Psychiatry 1996; 57 Suppl. 2: 19–23

    PubMed  CAS  Google Scholar 

  11. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 Suppl. 2: 46–52

    PubMed  CAS  Google Scholar 

  12. Feiger AD, Bielski RD, Bremner JD, et al. Efficacy of nefazodone in continuation treatment of depression [abstract no. NR371]. 149th Meeting of the American Psychiatric Association; 1996 May 4–9; New York, 168–169.

  13. Anton SF, Robinson DS, Roberts DL, et al. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 30(2): 165–9

    PubMed  CAS  Google Scholar 

  14. Robinson DS, Roberts DL, Smith JM, et al. The safety profile of nefazodone. J Clin Psychiatry 1996; 57 Suppl. 2: 31–8

    PubMed  CAS  Google Scholar 

  15. Lader MH. Tolerability and safety: essentials in antidepressant pharmacotherapy. J Clin Psychiatry 1996; 57 Suppl. 2: 39–44

    PubMed  CAS  Google Scholar 

  16. Bristol-Myers Squibb. Nefazodone prescribing information. Princeton, New Jersey, USA, 1996

    Google Scholar 

  17. Aronoff GM. Trazodone associated with priapism [letter]. Lancet 1984 Apr 14; 1: 856

    Article  PubMed  CAS  Google Scholar 

  18. von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 Suppl. 1: 33–44

    Article  Google Scholar 

  19. Revicki DA, Brown RE, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995 Dec; 8: 524–40

    Article  PubMed  CAS  Google Scholar 

  20. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull 1995; 31(2): 249–58

    PubMed  CAS  Google Scholar 

  21. Montgomery SA, Brown RE, Clark M. Economic analysis of treating depression with nefazodone v. imipramine. Br J Psychiatry 1996 Jun; 168:768–71

    Article  PubMed  CAS  Google Scholar 

  22. Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995; 4(4): 261–77

    Article  CAS  Google Scholar 

  23. Frank E, Prien RF, Jarrett RB, et al. Conceptualisation and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse and recurrence. Arch Gen Psychiatry 1991; 48: 851–5

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nefazodone: a better tolerated option than TCAs for major depression. Drugs Ther. Perspect 10, 1–7 (1997). https://doi.org/10.2165/00042310-199710080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199710080-00001

Keywords

Navigation